Walleye Capital’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-300
Closed -$3.5K – 5985
2026
Q2
$3.5K Sell
300
-3,300
-92% -$47.1K ﹤0.01% 4562
2026
Q1
$60.4K Buy
+3,600
New +$64.4K ﹤0.01% 3843
2025
Q4
– Sell
-100
Closed -$1.24K – 4625
2025
Q3
$1.24K Sell
100
-7,000
-99% -$82.1K ﹤0.01% 4370
2025
Q2
$81.8K Buy
+7,100
New +$84.2K ﹤0.01% 3862
2024
Q4
– Sell
-17,500
Closed -$324K – 4923
2024
Q3
$324K Buy
17,500
+10,000
+133% +$201K ﹤0.01% 3669
2024
Q2
$152K Buy
+7,500
New +$133K ﹤0.01% 4482
2019
Q4
– Sell
-6,700
Closed -$312K – 1845
2019
Q3
$312K Buy
+6,700
New +$311K 0.02% 965

Other funds holding CLB

Walleye Capital's CLB Position: Q3 2026 in Review

Walleye Capital sold out of Core Laboratories (CLB) in Q3 2026, closing a stake of 20,687 shares — an estimated $241K sold.

Walleye Capital first reported a position in CLB in Q3 2024 and held it in 2 quarters. The position peaked at $241K in Q2 2026. 179 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Walleye Capital reported no remaining Core Laboratories position as of Q3 2026 after selling out during the quarter.
  • Walleye Capital sold 20,687 Core Laboratories shares in Q3 2026, an estimated $241K.
  • Walleye Capital first reported a position in Core Laboratories in Q3 2024 and held it in 2 quarters.
  • Walleye Capital's Core Laboratories position peaked at $241K in Q2 2026.
  • 179 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.